Icon

HEMABATE (nda017989)- (EQ 0.25MG BASE/ML)

CARBOPROST TROMETHAMINE PFIZER
EQ 0.25MG BASE/ML
No No
Expired Expired
None None
None No
HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. HEMABATE is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations.
12 0 11
Total Other Developers 22
Drugs with Suitability No
EQ 0.25MG BASE/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ****** ****** *************** ******* ******* *********** **** **. **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***. ******, *********, ** ******, ***** (***) ***
****** **** ***** ****** ************* ***. *********** *** ********* ** *'*********, *******, ** *** ***, ****** (***) ***
****** ****** ****** ******** ******* *********** ****** **.*** & ***. ******************, **************** (****), *********** (********), *************, ***** **** ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ******** ***, **** **. ****/****, ******* - *********, ****** - *****, ********, ******* ******, ***** (***) ***
****** ************ ******* ********* ********* ****** ******* *********** **** **.: *-**, ************ ********** ****, **************, *** *****, ****, ************** *****, ********* *****, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** **: **-**, **, **, **-**, **. **. ***, ***, *** & ***, ***** ***, *****, ************ *******, ********** ******, ********** ********, *********, ********* ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** ***-***, ** *****, ****** **** ****, *****, *********** ********** ****, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.